Weaver F A, Comerota A J, Youngblood M, Froehlich J, Hosking J D, Papanicolaou G
Division of Vascular Surgery, University of Southern California School of Medicine, Los Angeles 90033-4612, USA.
J Vasc Surg. 1996 Oct;24(4):513-21; discussion 521-3. doi: 10.1016/s0741-5214(96)70067-8.
Early results of a prospective study that compared surgical revascularization and thrombolysis for lower extremity arterial and graft occlusions have been published. This report details the final results in patients who have native artery occlusions.
Two hundred thirty-seven patients who had lower extremity ischemia as a result of iliac-common femoral (IF; 69 patients) or superficial femoral-popliteal (FP; 168 patients) occlusion, and had symptomatically deteriorated within the past 6 months were randomized to catheter-directed thrombolysis (150 patients) or surgical revascularization (87 patients). After diagnostic arteriographic examination but before randomization, the optimal surgical procedure was determined. Lytic patients were randomized to recombinant tissue plasminogen activator (rt-PA; 84 patients) or urokinase (UK; 66 patients). Recurrent ischemia, morbidity, amputation, and death rates were determined at 30 days, 6 months, and 1 year, and were analyzed on an intent-to-treat basis.
For patients randomized to lysis, a catheter was properly positioned and the lytic agent delivered in 78%. This provided a reduction in the predetermined surgical procedure in 58% of patients who had an FP occlusion and 51% of those who had an IF occlusion. rt-PA and UK were equally effective and safe, but lysis time was shorter with rt-PA (8 vs 24 hr; p < 0.05). At 1 year, the incidence of recurrent ischemia (64% vs 35%; p < 0.0001) and major amputation (10% vs 0%; p = 0.0024) was increased in patients who were randomized to lysis. Factors associated with a poor lytic outcome included FP occlusion, diabetes, and critical ischemia. No differences in mortality rates were observed at 1 year between the lysis and surgical groups.
Surgical revascularization for lower extremity native artery occlusions is more effective and durable than thrombolysis. Thrombolysis used initially provides a reduction in the surgical procedure for a majority of patients; however, long-term outcome is inferior, particularly for patients who have an FP occlusion, diabetes, or critical ischemia.
一项比较手术血运重建与溶栓治疗下肢动脉及移植物闭塞的前瞻性研究的早期结果已发表。本报告详述了患有天然动脉闭塞患者的最终结果。
237例因髂总股动脉(IF;69例患者)或股浅腘动脉(FP;168例患者)闭塞导致下肢缺血且在过去6个月内症状恶化的患者被随机分为导管定向溶栓组(150例患者)或手术血运重建组(87例患者)。在诊断性血管造影检查后但在随机分组前,确定最佳手术方案。溶栓组患者被随机分为重组组织型纤溶酶原激活剂(rt-PA;84例患者)或尿激酶(UK;66例患者)组。在30天、6个月和1年时确定复发性缺血、发病率、截肢率和死亡率,并按意向性治疗进行分析。
对于随机分组至溶栓组的患者,78%的患者导管定位正确且溶栓剂已给药。这使得58%的FP闭塞患者和51%的IF闭塞患者的预定手术方案得以减少。rt-PA和UK同样有效且安全,但rt-PA的溶栓时间更短(8小时对24小时;p<0.05)。1年时,随机分组至溶栓组的患者复发性缺血发生率(64%对35%;p<0.0001)和大截肢率(10%对0%;p = 0.0024)增加。与溶栓效果不佳相关的因素包括FP闭塞、糖尿病和严重缺血。1年时,溶栓组和手术组之间的死亡率无差异。
下肢天然动脉闭塞的手术血运重建比溶栓更有效且持久。最初使用溶栓可减少大多数患者的手术操作;然而,长期结果较差,特别是对于患有FP闭塞、糖尿病或严重缺血的患者。